Vascular Therapies
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
105 Union Ave, Cresskill, New Jersey, 07...Phone Number
(201) 266-8310Website
www.vasculartx.comRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Vascular Therapies
Vascular Therapies, Inc., is a privately held, biopharma company developing Sirogen, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this therapeutic approach is to improve vascular surgery outcomes in patients with kidney and vascular diseases. This investigational therapy is currently being evaluated in a Phase 3 randomized clinical trial, which is being performed under a Special Protocol Assessment (SPA). The drug development program has received Fast Track status from the FDA and sirolimus has Orphan Drug Designation for dialysis vascular access indications in the U.S. and E.U. The FDA has tentatively approved the proprietary tradename Sirogen. Sirogen is an investigational product and has not been determined by the FDA to be safe and effective for any use.Explore more
Vascular Therapies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vascular Therapies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Vascular Therapies
Click to see if Vascular Therapies had a recent Job posting/layoffs
Product Launch: Get notified when Vascular Therapies launches new products
Check out if Vascular Therapies is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Vascular Therapies has new funding data
Check if Vascular Therapies has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Vascular Therapies recently announced quarterly report
Vascular Therapies, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Vascular Therapies
Compare insights from companies similar to Vascular Therapies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vascular Therapies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vascular Therapies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vascular Therapies.
Vascular Therapies financials insights
Gather financial insights about Vascular Therapies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Private Equity
$17.3M
2022
Unspecified
$25M
Vascular Therapies Tech Stack
A closer look at the technologies used by Vascular Therapies
Vascular Therapies News & Media
Vascular Therapies Announces Presentation of Phase 3 Clinical Trial Results at the American Society of Nephrology Meeting
CRESSKILL, N.J., Nov. 4, 2021 /PRNewswire/ -- Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today, the company announced the...Vascular Therapies Announces Clinical Results From Its Phase 3 Randomized Multicenter Clinical Trial
CRESSKILL, N.J.--(BUSINESS WIRE)--Vascular Therapies Announces Clinical Results from its Phase 3 Randomized Multicenter Clinical TrialVascular Therapies to Participate in the SVB Leerink 9th Annual Global Healthcare Conference
CRESSKILL, N.J.--(BUSINESS WIRE)--Vascular Therapies to Participate in the SVB Leerink 9th Annual Global Healthcare ConferenceVascular Therapies Completes Upsized $17.3 Million Private Financing
CRESSKILL, N.J,--(BUSINESS WIRE)--Vascular Therapies Completes Upsized $17.3 Million Private Financing
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vascular Therapies
Sign Up For FreeTo access detailed company insights
Vascular Therapies, Inc., is a privately held, biopharma company developing Sirogen, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this therapeutic approach is to improve vascular surgery outcomes in patients with kidney and vascular diseases. This investigational therapy is currently being evaluated in a Ph... Read More
